Literature DB >> 9038263

Overexpression of cyclin D1 in epithelial ovarian cancers.

S D Worsley1, B A Ponder, B R Davies.   

Abstract

Amplification and overexpression of the cell cycle-related gene cyclin D1 have been demonstrated in several human malignancies and have been shown to be directly oncogenic in breast epithelium and lymphocytes. Overexpression of the gene can occur in the absence of gene amplification. We have investigated whether cyclin D1 is overexpressed in a panel of 43 sporadic epithelial ovarian cancers using immunohistochemistry. Cyclin D1 was overexpressed in 26% of these tumors. Overexpression of cyclin D1 is associated with borderline or well-differentiated, grade 1 tumors but does not correlate with a particular histological type, overexpression of the c-erb-B2 oncogene, or presence of estrogen receptors. It is suggested that overexpression of cyclin D1 may contribute to the pathogenesis of epithelial ovarian cancers, including a subset of tumors different from those overexpressing the c-erb-B2 oncogene.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9038263     DOI: 10.1006/gyno.1996.4569

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  25 in total

Review 1.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

2.  The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor.

Authors:  Dan Zhang; Hexia Xia; Wei Zhang; Bo Fang
Journal:  Tumour Biol       Date:  2015-08-21

3.  Cyclin D1 predicts the prognosis of advanced serous ovarian cancer.

Authors:  Tomoko Hashimoto; Nozomu Yanaihara; Aikou Okamoto; Takashi Nikaido; Misato Saito; Satoshi Takakura; Makoto Yasuda; Hiroshi Sasaki; Kazunori Ochiai; Tadao Tanaka
Journal:  Exp Ther Med       Date:  2011-01-18       Impact factor: 2.447

4.  PI3K/Akt/JNK/c-Jun signaling pathway is a mediator for arsenite-induced cyclin D1 expression and cell growth in human bronchial epithelial cells.

Authors:  Jin Ding; Beifang Ning; Yi Huang; Dongyun Zhang; Jingxia Li; Chang-Yan Chen; Chuanshu Huang
Journal:  Curr Cancer Drug Targets       Date:  2009-06       Impact factor: 3.428

Review 5.  Cyclin D1 and human neoplasia.

Authors:  R Donnellan; R Chetty
Journal:  Mol Pathol       Date:  1998-02

6.  Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo.

Authors:  Wei Li; Hong-Ru Jiang; Xiao-Li Xu; Jie Wang; Jun Zhang; Mei-Lin Liu; Ling-Yun Zhai
Journal:  Int J Mol Sci       Date:  2010-10-19       Impact factor: 5.923

7.  NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.

Authors:  Y Yu; F Xu; H Peng; X Fang; S Zhao; Y Li; B Cuevas; W L Kuo; J W Gray; M Siciliano; G B Mills; R C Bast
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

Review 8.  New insights on the role of hormonal therapy in ovarian cancer.

Authors:  Fiona Simpkins; Arlene Garcia-Soto; Joyce Slingerland
Journal:  Steroids       Date:  2013-02-08       Impact factor: 2.668

9.  The expression of HER-2/neu (c-erbB2), survivin and cycline D1 in serous ovarian neoplasms: their correlation with clinicopathological variables.

Authors:  Gulay Turan; Ceyda Sancakli Usta; Akin Usta; Mehmet Kanter; Lema Tavli; Meric Karacan; Cetin Celik; Metin Eser
Journal:  J Mol Histol       Date:  2014-08-09       Impact factor: 2.611

10.  Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms.

Authors:  Mehmet Kanter; Gulay Turan; Ceyda Usta; Akin Usta; H Hasan Esen; Lema Tavlı; Cetin Celik; Yusuf Demirkol; Betül Kanter
Journal:  J Mol Histol       Date:  2016-01-27       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.